HekeTiss

Executive Summary

HekeTiss SA is a Swiss biotech spin-off from the University of Geneva and Geneva University Hospitals, founded in 2018, focused on regenerative therapies for chronic wounds. Its lead product, TrophiPatch™, is an off-the-shelf, adipose-derived stem cell-based patch designed to stimulate vascularization and accelerate healing, primarily targeting diabetic foot ulcers and other vascular-related skin ulcers. The company has strong academic roots and a differentiated approach in the cell-based wound healing market, which is large and underserved. With an off-the-shelf format, TrophiPatch™ could offer advantages over autologous cell therapies in terms of cost, consistency, and ease of use. HekeTiss is currently advancing preclinical or early clinical studies, and its success hinges on demonstrating efficacy in upcoming trials and securing partnerships for manufacturing and distribution. The company represents an early-stage, high-risk but potentially high-reward opportunity in the regenerative medicine space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical trial interim data readout for TrophiPatch in diabetic foot ulcers35% success
• Q4 2026FDA Orphan Drug Designation or EMA orphan designation for TrophiPatch65% success
• H1 2027Strategic partnership with a wound care or regenerative medicine company for co-development/commercialization30% success